, Tracking Stock Market Picks
Enter Symbol:
Cardium Therapeutics Inc. (CRXM) [hlAlert]

down 99.31 %

CoBiz, Inc. (CXM) rated Buy

Posted on: Wednesday,  Oct 3, 2007  9:25 AM ET by Oppenheimer

Oppenheimer rated Buy Cardium Therapeutics Inc. (OTCBB: CRXM) on 10/03/2007, when the stock price was $56.80. Since
then, Cardium Therapeutics Inc. has lost 99.31% as of 08/27/2015's recent price of $0.39.
If you would have followed this Oppenheimer's recommendation on CRXM, you would have lost 99.31% of your investment in 2885 days.

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium?s lead product candidate, Generx (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/3/2007 9:25 AM Buy
56.80 100.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy